Being immunocompromised makes CLL patients one of the most vulnerable patient groups
Clinical haematologist and researcher, Associate Professor Nada Hamad discusses the latest on CLL.
- Chronic lymphocytic leukaemia
- Treatments and side-effects
Clinical haematologist and researcher, Associate Professor Nada Hamad discusses the latest on CLL.
Don Hayes had an allogeneic stem cell transplant days before his 71st birthday.
For the third time, selinexor (Xpovio®) will be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November 2022 meeting for the treatment of relapsed/refractory (R/R) myeloma.
Daratumumab (Darzalex®) could be the first ever therapy to be approved in Australia for AL amyloidosis.
The Leukaemia Foundation has welcomed news that for the first time, a targeted treatment option will now be available for Waldenström macroglobulinemia (WM) patients through the Pharmaceutical Benefits Scheme (PBS).
It’s 10 years since the first CLL patients were treated with CAR T-cell therapy and they are still in remission.